Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1997; 29:1199-1205
© 1997 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nul, D.
Right arrow Articles by Scapin, O
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nul, D.
Right arrow Articles by Scapin, O

Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicentricos en Argentina

DR Nul, HC Doval, HO Grancelli, SD Varini, S Soifer, SV Perrone, N Prieto, and O Scapin

OBJECTIVES: The impact of amiodarone on mortality in patients with severe congestive heart failure (CHF) (New York Heart Association functional classes II [advanced], III and IV; left ventricular ejection fraction < 35%) In the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) trial was analyzed in relation to initial mean baseline heart rate (BHR) and its change after 6 months of follow-up. BACKGROUND: Trials of amiodarone therapy in CHF have produced discordant results, suggesting that the effect is not uniform in all patient subgroups with regard to survival. METHODS: The present analysis was carried out in 516 patients randomized to receive amiodarone, 300 mg/day (n = 260), or nonantiarrhythmic therapy (n = 256, control group) and followed up for 2 years. Survival was evaluated for patients with a BHR > or = 90 beats/min (control: n = 132; amiodarone: n = 122) and < 90 beats/min (control: n = 124; amiodarone: n = 138). Survival was also analyzed according to heart rate reduction at 6 months for 367 patients. RESULTS: For patients with a BHR > or = 90 beats/min, amiodarone therapy reduced mortality to 38.4% compared with 62.4% in control patients (relative risk [RR] 0.55, 95% confidence interval [CI] 0.35 to 0.95, p < 0.002). Both sudden death (RR 0.46, 95% CI 0.24 to 0.90, p < 0.02) and progressive heart failure death (RR 0.60, 95% CI 0.30 to 1.03, p < 0.06) were reduced, and functional capacity was improved. In patients with a BHR < 90 beats/min, amiodarone did not alter survival. Among 367 patients who completed 6 months of follow-up, amiodarone reduced 2-year mortality only in those with a BHR > or = 90 beats/min, which was reduced at 6 months. CONCLUSIONS: Elevated rest heart rates in severe CHF identify a subgroup of patients who benefit from treatment with amiodarone. Amiodarone-induced heart rate slowing may be an important benefit for patients.


This article has been cited by other articles:


Home page
Eur Heart JHome page
R. Kolloch, U. F. Legler, A. Champion, R. M. Cooper-DeHoff, E. Handberg, Q. Zhou, and C. J. Pepine
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST)
Eur. Heart J., May 2, 2008; 29(10): 1327 - 1334.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A S Hall and S Palmer
The heart rate hypothesis: ready to be tested
Heart, May 1, 2008; 94(5): 561 - 565.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
C. Melzer, J. Witte, R. Reibis, H.J. Bondke, W. Combs, K. Stangl, G. Baumann, and H. Theres
Predictors of chronotropic incompetence in the pacemaker patient population.
Europace, January 1, 2006; 8(1): 70 - 75.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. Metra, C. Torp-Pedersen, K. Swedberg, J. G.F. Cleland, A. Di Lenarda, M. Komajda, W. J. Remme, B. Lutiger, A. Scherhag, M. A. Lukas, et al.
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
Eur. Heart J., November 1, 2005; 26(21): 2259 - 2268.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
B. N. Singh
More on Amiodarone-Meeting the Challenges of the Combined Epidemics of Heart Failure and Atrial Fibrillation?
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 175 - 178.
[PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
D. C. Choo, B. Huiskes, J. Jones, S. Fabbri, L. A. Hawkins, K. Chatterjee, T. De Marco, and J. T. Heywood
Amiodarone Rescue Therapy for Severe Decompensated Heart Failure Initially Unsuitable for {beta}-Blockers
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 187 - 192.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
L. Tavazzi
Heart rate as a therapeutic target in heart failure?
Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G15 - G18.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
J.P. Vilaine, C. Thollon, N. Villenueve, and J.L. Peglion
Procoralan, a new selective If current inhibitor
Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G26 - G35.
[Abstract] [PDF]


Home page
NEJMHome page
A. Malhotra, V. V. Muse, and E. J. Mark
Case 12-2003 - An 82-Year-Old Man with Dyspnea and Pulmonary Abnormalities
N. Engl. J. Med., April 17, 2003; 348(16): 1574 - 1585.
[Full Text] [PDF]


Home page
HeartHome page
R H Arnold, E Kotlyar, C Hayward, A M Keogh, and P S Macdonald
Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: a single centre, observational study
Heart, March 1, 2003; 89(3): 293 - 298.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
D. J. van Veldhuisen and W. H. van Gilst
The pharmacological management of heart failure: too many treatments?
Eur J Heart Fail, January 1, 2003; 5(1): 5 - 8.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
R.A de Boer and D.J van Veldhuisen
Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D111 - D116.
[Abstract] [PDF]


Home page
CirculationHome page
H. Yonemochi, S. Yasunaga, Y. Teshima, N. Takahashi, M. Nakagawa, M. Ito, and T. Saikawa
Rapid Electrical Stimulation of Contraction Reduces the Density of {beta}-Adrenergic Receptors and Responsiveness of Cultured Neonatal Rat Cardiomyocytes : Possible Involvement of Microtubule Disassembly Secondary to Mechanical Stress
Circulation, June 6, 2000; 101(22): 2625 - 2630.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Malik, A. J. Camm, M. J. Janse, D. G. Julian, G. A. Frangin, P. J. Schwartz, and on behalf of the EMIAT Investigators
Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial)
J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1263 - 1275.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. M. Kaye, A. M. Dart, G. L. Jennings, and M. D. Esler
Antiadrenergic effect of chronic amiodarone therapy in human heart failure
J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1553 - 1559.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
T Laperche, D Logeart, A Cohen-Solal, and R Gourgon
Potential interests of heart rate lowering drugs
Heart, April 1, 1999; 81(4): 336 - 341.
[Full Text]


Home page
Arch Intern MedHome page
P. Palatini, E. Casiglia, S. Julius, and A. C. Pessina
High Heart Rate: A Risk Factor for Cardiovascular Death in Elderly Men
Arch Intern Med, March 22, 1999; 159(6): 585 - 592.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Palatini
Need for a Revision of the Normal Limits of Resting Heart Rate
Hypertension, February 1, 1999; 33(2): 622 - 625.
[Full Text] [PDF]


Home page
CirculationHome page
M. Zabel, T. Klingenheben, M. R. Franz, and S. H. Hohnloser
Assessment of QT Dispersion for Prediction of Mortality or Arrhythmic Events After Myocardial Infarction : Results of a Prospective, Long-term Follow-up Study
Circulation, June 30, 1998; 97(25): 2543 - 2550.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
R. P Steeds and K. S Channer
Drug treatment in heart failure
BMJ, February 14, 1998; 316(7131): 567 - 568.
[Full Text]


Home page
Journal Watch CardiologyHome page
Who Benefits From Amiodarone?
Journal Watch Cardiology, May 19, 1997; 1997(519): 3 - 3.
[Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement